Literature DB >> 32839835

Therapeutic effects of ginsenosides on breast cancer growth and metastasis.

Yujin Jin1, Diem Thi Ngoc Huynh1, Thuy Le Lam Nguyen1, Hyesu Jeon1, Kyung-Sun Heo2,3.   

Abstract

Breast cancer is the most common cause of cancer-related deaths among women worldwide. Thus, the development of new and effective low-toxicity drugs is vital. The specific characteristics of breast cancer have allowed for the development of targeted therapy towards each breast cancer subtype. Nevertheless, increasing drug resistance is displayed by the changing phenotype and microenvironments of the tumor through mutation or dysregulation of various mechanisms. Recently, emerging data on the therapeutic potential of biocompounds isolated from ginseng have been reported. Therefore, in this review, various roles of ginsenosides in the treatment of breast cancer, including apoptosis, autophagy, metastasis, epithelial-mesenchymal transition, epigenetic changes, combination therapy, and drug delivery system, have been discussed.

Entities:  

Keywords:  Breast cancer; Cancer resistance; Cell growth; Epithelial-mesenchymal transition; Ginsenoside; Metastasis

Mesh:

Substances:

Year:  2020        PMID: 32839835     DOI: 10.1007/s12272-020-01265-8

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  9 in total

1.  Protective effects of ginsenoside-Rg2 and -Rh1 on liver function through inhibiting TAK1 and STAT3-mediated inflammatory activity and Nrf2/ARE-mediated antioxidant signaling pathway.

Authors:  Thuy Le Lam Nguyen; Diem Thi Ngoc Huynh; Yujin Jin; Hyesu Jeon; Kyung-Sun Heo
Journal:  Arch Pharm Res       Date:  2021-02-03       Impact factor: 4.946

2.  Rg3 and Rh2 ginsenosides suppress embryoid body formation by inhibiting the epithelial-mesenchymal transition.

Authors:  Jae Sung Noh; Jae Kyun Jeong; Jeung-Whan Han; Sang Ah Yi
Journal:  Arch Pharm Res       Date:  2022-06-27       Impact factor: 6.010

Review 3.  A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer.

Authors:  Muhammad Naeem; Muhammad Omer Iqbal; Humaira Khan; Muhammad Masood Ahmed; Muhammad Farooq; Muhammad Moeen Aadil; Mohamad Ikhwan Jamaludin; Abu Hazafa; Wan-Chi Tsai
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

4.  Ginsenoside Rh1 inhibits tumor growth in MDA-MB-231 breast cancer cells via mitochondrial ROS and ER stress-mediated signaling pathway.

Authors:  Yujin Jin; Diem Thi Ngoc Huynh; Kyung-Sun Heo
Journal:  Arch Pharm Res       Date:  2022-03-24       Impact factor: 4.946

5.  Ginsenoside Rh1 Inhibits Angiotensin II-Induced Vascular Smooth Muscle Cell Migration and Proliferation through Suppression of the ROS-Mediated ERK1/2/p90RSK/KLF4 Signaling Pathway.

Authors:  Diem Thi Ngoc Huynh; Yujin Jin; Dung Van Nguyen; Chang-Seon Myung; Kyung-Sun Heo
Journal:  Antioxidants (Basel)       Date:  2022-03-27

Review 6.  Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Authors:  Hong Wang; Yu Zheng; Qiang Sun; Zhen Zhang; Mengnan Zhao; Cheng Peng; Sanjun Shi
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

Review 7.  Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development.

Authors:  Ye Jin; Tianjia Liu; Haoming Luo; Yangyang Liu; Da Liu
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

8.  Fabrication of Ginsenoside-Based Nanodrugs for Enhanced Antitumor Efficacy on Triple-Negative Breast Cancer.

Authors:  Shuting Zuo; Jing Wang; Xianquan An; Zhenyu Wang; Xiao Zheng; Yan Zhang
Journal:  Front Bioeng Biotechnol       Date:  2022-08-12

9.  Ginsenoside-Rg2 exerts anti-cancer effects through ROS-mediated AMPK activation associated mitochondrial damage and oxidation in MCF-7 cells.

Authors:  Hyesu Jeon; Yujin Jin; Chang-Seon Myung; Kyung-Sun Heo
Journal:  Arch Pharm Res       Date:  2021-07-24       Impact factor: 4.946

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.